Molecular cytogenetic analysis of Korean patients with Waldenström macroglobulinemia

Bang, Soo Mee; Seo, Ji Weon; Park, Kyoung Un; Kim, Seok Jin; Kım, Kihyun; Kim, Sun Hee; Cho, Sung Ran; Kim, Hugh C.; Song, Jaewoo; Kim, Jin Seok; Kim, Kyung Hee; Lee, Jae Hoon; Lee, Je Jung; Shin, Myung Geun; Suh, Cheolwon; Sook, Hyun; Oh, Dong Young; Won, Jong Ho; Kim, Hyo Jung; Yoon, Sung Soo; Lee, Dong Hoon

doi:10.1016/j.cancergencyto.2009.11.008

Cited by 12 publications

(17 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common cytogenetic abnormality was deletion of the long arm of chromosome 6 (6q deletion) and trisomy 4 [15, 16]. However, there was only one report about cytogenetics of Korean WM patients, which documented a low rate of 6q deletion (10%) and no trisomy 4 [13]. Similar to a previous Korean study, this study documented a low rate of 6q deletion and other cytogenetic abnormalities.…”

Section: Discussionsupporting

confidence: 78%

Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenström Macroglobulinemia in Korea

Lee

Kım

Yoon

et al. 2014

BioMed Research International

Self Cite

View full text Add to dashboard Cite

Waldenström's macroglobulinemia (WM) is a B-cell proliferative malignancy characterized by immunoglobulin M monoclonal gammopathy and bone marrow infiltration by lymphoplasmacytic cells. Clinical features and cytogenetics of WM in Asia including Republic of Korea remain unclear. Moreover, no study has reported treatment outcomes in patients with WM treated with novel agent combined with conventional chemotherapy. This study investigated clinical features and assessed treatment outcomes with novel agent and conventional chemotherapy in Republic of Korea. Data from all (n = 71) patients with newly diagnosed WM at 17 hospitals who received chemotherapy between January 2005 and December 2012 were collected retrospectively. The median age of patients was 66 years (range: 37–92 years) and male to female ratio was 5 : 1. Patients treated with novel agent combined chemotherapy displayed higher overall response rate (ORR) compared to conventional chemotherapy alone (92.9% versus 52.6%, P = 0.006). The 5-year overall survival rate was 62.6% (95% confidence interval: 34.73–111.07). Use of novel agents produced higher ORR but survival benefit was not apparent due to the small number of patients and short follow-up duration. Further studies are needed to confirm the efficacy of novel agents in patients with WM.

show abstract

Section: Discussionsupporting

confidence: 78%

Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenström Macroglobulinemia in Korea

Lee

Kım

Yoon

et al. 2014

BioMed Research International

Self Cite

View full text Add to dashboard Cite

show abstract

“…The 6q deletion was the most frequent abnormality and was found in 37% of Korean patients. Previous studies performed in Western patients with WM reported the frequency of 6q deletions to be 32–54%, identified using FISH [21–24]. Previously, we reported a lower frequency of 6q deletions (10%) in Korean patients compared with Caucasians [24].…”

Section: Discussionmentioning

confidence: 73%

MYD88 L265P Mutations Are Correlated with 6q Deletion in Korean Patients with Waldenström Macroglobulinemia

Kim

Park

et al. 2014

BioMed Research International

Self Cite

View full text Add to dashboard Cite

Waldenström macroglobulinemia (WM) is a malignant lymphoplasma-proliferative disorder with IgM monoclonal gammopathy. A recent whole-genome study identified MYD88 L265P as the key mutation in WM. We investigated MYD88 mutations in conjunction with cytogenetic study in 22 consecutive Korean WM patients. Conventional G-banding and interphase fluorescence in situ hybridization (FISH) were performed at regions including 6q21 using bone marrow (BM) aspirates. Sixteen patients were subjected to Sanger sequencing-based MYD88 mutation study. Five patients (28%) showed cytogenetic aberrations in G-banding. The incidence of 6q21 deletion was 17% by conventional G-banding and 37% by FISH. Ten patients (45%) showed cytogenetic aberrations using FISH: 6q deletion in eight (37%) and IGH rearrangement in four (18%). Two patients had both the 6q deletion and IGH rearrangement, and two had only the IGH rearrangement. Eleven patients (69%) presented with the MYD88 L265P mutation. MYD88 mutations were significantly associated with the presence of 6q deletions (P = 0.037). Six patients with the 6q deletion for whom sequencing was possible were found to harbor MYD88 mutations. The MYD88 L265P mutation was also associated with increased lymphocyte burden in BM biopsy. This is the first report of high frequency MYD88 L265P mutations in Korean WM patients.

show abstract

“…We published the cytogenetic characteristics of Korean myeloma patients as previously described [22]. A similar study was performed in Waldenstrom macroglobulinemia (WM) this year [40]. We found the difference in cytogenetic characteristics between MM and WM.…”

mentioning

confidence: 80%

Molecular cytogenetic analysis of Korean patients with Waldenström macroglobulinemia

Cited by 12 publications

References 27 publications

Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenström Macroglobulinemia in Korea

Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenström Macroglobulinemia in Korea

MYD88 L265P Mutations Are Correlated with 6q Deletion in Korean Patients with Waldenström Macroglobulinemia

Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party

Contact Info

Product

Resources

About